

FOR PATIENTS



KINPEYGO[®] ▼ 4 mg
Modified-release hard capsules
budesonide

Patient Information

for patients who have been prescribed Kinpeygo[®]

Always read the Patient Information Leaflet, this is not a substitute for the Patient Information Leaflet.

Always use the medicine as your doctor has told you.

Why have I been prescribed Kinpeygo®

Kinpeygo® is indicated for the treatment of IgA Nephropathy (IgAN).¹

IgA Nephropathy (IgAN) is the most common form of **glomerulonephritis, an inflammation of the glomeruli**, the filtration units of our kidneys. The disease is triggered by processes in which the **antibody immunoglobulin A (IgA)** plays a central role.² In the course of IgA Nephropathy, so-called immune complexes are deposited in the glomeruli. These deposits lead to inflammatory changes which can damage the kidneys and severely limit their function.^{3,4} Another name for IgA Nephropathy (from the Greek words “nephros”, meaning “kidney”, and “pathos”, meaning “disease”) is **Berger’s disease**.⁴⁻⁶

IgA Nephropathy **at a Glance**




IgAN is an orphan disease that **affects approximately 200,000 people** in the EU and in the UK⁷



IgAN is the **most common form** of glomerulonephritis^{8,9}



IgAN most frequently develops in individuals **aged 16 to 35 years**⁴



It affects **twice as many men** as women¹⁰

What is Kinpeygo^{®1}

Kinpeygo[®] contains the active substance budesonide, a corticosteroid medicine which mainly acts locally in the intestine to reduce the inflammation associated with primary immunoglobulin A (IgA) nephropathy. Kinpeygo[®] is used to treat primary IgA nephropathy in adults 18 years of age or older

How to take Kinpeygo^{®1}

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.



The recommended dose of Kinpeygo[®] is 16 mg (4 capsules of Kinpeygo[®] 4 mg) once daily



Take in the morning, at least 1 hour before a meal



Swallow whole with a glass of water

Do not open, crush or chew – as this could affect the release of the medicine

The capsules have a special coating, to ensure that the medicine is released in the correct part of your gut.

When treatment is to be discontinued, your doctor will reduce the dose to 8 mg (2 capsules of Kinpeygo[®] 4 mg) once daily for the last 2 weeks of therapy. If considered necessary by your doctor, the dose may then be reduced to 4 mg once daily (1 capsule of Kinpeygo[®] 4 mg) for another 2 weeks.

What **side effects** can I expect?

Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor, pharmacist or nurse if you notice any of the following side effects with this medicine:

Very common (may affect more than 1 in 10 people)¹

- Rash or itchy skin
- Acne
- Reduced potassium levels in the blood (hypokalaemia)

Common (may affect up to 1 in 10 people)¹

- Increased blood pressure
- Swelling of arms or legs – such as ankle swelling
- Swelling of the face
- Cushingoid features such as a rounded face, increased body hair and weight gain
- Indigestion
- Muscle cramps
- Weight gain
- Diabetes mellitus
- Increase in the number of white blood cells (detected by blood tests)

Rare (may affect up to 1 in 1,000 people)¹

- Blurred vision

For full details on administration and possible side effects please refer to the **Patient Information Leaflet** that comes enclosed in your Kinpeygo[®] medication pack.

What can you, **as a patient**, do?

Follow-up visits to the doctor and taking prescribed medications regularly are important components of living with IgAN. Moreover, you can also contribute a lot to improving your health and maintaining your quality of life:⁸



Try to **reduce any excess bodyweight** and exercise regularly



A diet with **reduced salt** content can help lower high blood pressure



Protect yourself from infections. Vaccine protection also plays an important role. Make sure to have the **standard vaccinations refreshed regularly** and ask your doctor **which additional vaccinations may be useful for you**




If you smoke, you should **give up cigarettes completely, if possible**



Connect with other people with kidney disease to **share your experiences**

Ask your doctor for advice before starting a new exercise programme or changing your diet. They can also advise you on aids that can help you stop smoking.



Where can I find more information?



Click or scan the QR code for further information and useful resources on Kinpeygo® or visit kinpeygotpatient.co.uk

1. Kinpeygo® Patient Information Leaflet.
2. Chang S, Li XK. Front Med (Lausanne). 2020;7:92.
3. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). [IgA Nephropathy](#). Accessed: June 2026.
4. Mayo Clinic. [IgA nephropathy \(Berger disease\)](#). Accessed: June 2026.
5. Etymonline. [Nephros](#). Accessed: June 2026.
6. Etymonline. [Pathos](#). Accessed: June 2026.
7. EMA. [European Public Assessment Report \(EPAR\): Kinpeygo](#). Accessed: June 2026.
8. Kidney Disease: [Improving Global Outcomes \(KDIGO\) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](#). In: Kidney Int 2021;100(4S): 1–276.
9. Du Y, et al. Diagnostics (Basel). 2023;13(2):303.
10. O'Shaughnessy MM, et al. Nephrol Dial Transplant. 2018;33(4):661-669.

Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Visit yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store to see how to report side effects.